SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):  October 26, 2018
MERIDIAN BIOSCIENCE, INC.
(Exact name of registrant as specified in its charter)

Ohio
0-14902
31-0888197
(State or other jurisdiction of incorporation)
(Commission File Number)
 
(IRS Employer Identification No.)

3471 River Hills Drive, Cincinnati, Ohio
45244
(Address of principal executive offices)
(Zip Code)

Registrant's telephone number, including area code  (513) 271-3700

(Former name or former address, if changed since last report.)
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
 
 ☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 ☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 ☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 ☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17CFR §240.12b-2).
Emerging growth company ☐
 
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐

Item 5.02.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On October 26, 2018, Susan D. Rolih, Executive Vice President, Global Regulatory and Quality Systems, of Meridian Bioscience, Inc. (the "Company") notified the Company of her retirement from that position effective November 30, 2018.

Ms. Rolih's retirement occurs in the context of the Company's executive succession planning activities that began in the Company's 2017 fiscal year. In August 2017, the Company hired Mr. Charles Thornton as Vice President, Regulatory Affairs and Quality Assurance, for the Company's Diagnostics business. In April 2018, the Company promoted Mr. Christopher Weatherall to the position of Vice President, Regulatory, Quality Assurance and Quality Control, for the Company's Life Science business. The Company expresses its sincere appreciation for Ms. Rolih's eighteen years of loyal service.
 
The Company and Ms. Rolih plan to enter into a consulting agreement in which Ms. Rolih would assist the Company on an as-requested basis with matters related to FDA remediation efforts at Magellan Diagnostics, among other matters.
 
SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
   
MERIDIAN BIOSCIENCE, INC.
     
Date:  November 1, 2018
  
By: /s/ Melissa A. Lueke
   
Executive Vice President and Chief Financial Officer
   
(Principal Financial and Accounting Officer)